Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUQO86)

Drug Name

IM-491 Drug Info

Synonyms

IM-491; UNII-UG82Y9C069; CHEMBL134908; UG82Y9C069; SCHEMBL6444631; BDBM50136259; 2,3-Piperidinedicarboxamide, N3-hydroxy-1-methyl-N2-(4-((2-methyl-4-quinolinyl)methoxy)phenyl)-, (2S,3S)-; 252918-63-1; (2S,3S)-N3-hydroxy-1-methyl-N2-(4-((2-methylquinolin-4-yl)methoxy)phenyl)piperidine-2,3-dicarboxamide; (2S,3S)-1-Methyl-piperidine-2,3-dicarboxylic acid 3-hydroxyamide 2-{[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-amide}

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 9889867
CAS Number: CAS 252918-63-1
TTD Drug ID: DMUQO86

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting TNF alpha converting enzyme (ADAM17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apratastat	DM8W4N9	Rheumatoid arthritis	FA20	Phase 2	[2]
Aderbasib	DMYOMSC	Breast cancer	2C60-2C65	Phase 1/2	[3]
GW-3333	DM3PMAZ	Chronic obstructive pulmonary disease	CA22	Preclinical	[4]
DPC-333	DM4JBQD	Inflammatory bowel disease	DD72	Terminated	[4]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[5]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[6]
SL422	DM3I2US	Discovery agent	N.A.	Investigative	[7]
PKF-242-484	DMNDLAS	Discovery agent	N.A.	Investigative	[8]
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	DMWXUCT	Discovery agent	N.A.	Investigative	[9]
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	DMA6EPH	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TNF alpha converting enzyme (ADAM17)	TT6AZXG	ADA17_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):241-6.
2	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
5	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94.
6	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
7	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
8	Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009 Jan 15;17(2):444-59.
9	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.